Table 2.
Baseline characteristics comparison within Cohort 2 (PP vs MD groups)
| Characteristic | Cohort 2 (PP) N = 103 |
Cohort 2 (MD) N = 33 |
P value |
|---|---|---|---|
| Age, (years) mean ± SD | 66 ± 9.1 | 65 ± 6.2 | NS |
| Male gender, N (%) | 69 (67%) | 26 (79%) | NS |
| Weight, (kg) mean ± SD | 87 ± 20.8 | 97 ± 23.9 | < 0.035 |
| BMI, (kg/m2) mean ± SD | 30.3 ± 6.2 | 32 ± 7.6 | NS |
| Diabetes type, N (%) | |||
| - Type 1 | 8 (7.8%) | 2 (6.1%) | NS |
| - Type 2 | 90 (87.4%) | 30 (90.9%) | NS |
| - Unknown | 5 (4.9%) | 1 (3%) | NS |
| Diabetes therapy, N (%) | |||
| - Insulin | 39 (37.9%) | 23 (69.7%) | < 0.002 |
| - Oral therapy | 57 (55.3%) | 9 (27.3%) | NS |
| BGL, (mmol/L) | |||
| - Mean ± SD | 14.2 ± 2.7 | 14.8 ± 2.3 | NS |
| - Range | 10.4–24.3 | 10.4–19.5 | |
PP per protocol, MD modified dose, SD standard deviation, N number, BMI body mass index, BGL blood glucose level, NS not significant (P > 0.05)